Tempus AI Shares Plunge 3.83% Amid Legal Scrutiny as $310M Trading Volume Ranks 389th in Market Activity

On August 6, 2025, Tempus AI (TEM) closed down 3.83% with a trading volume of $0.31 billion, ranking 389th in market activity. The decline followed renewed scrutiny over the company’s business practices and partnerships. A series of class action lawsuits allege misleading disclosures regarding revenue-generating contracts, joint venture credibility, and billing practices at its acquired subsidiary Ambry. The lawsuits highlight concerns about inflated contract values, including self-funded agreements and non-binding opt-ins, as well as risks tied to a SoftBank partnership perceived as facilitating artificial revenue growth.

Further allegations include AstraZeneca’s reduced financial commitments to Tempus through a questionable "pass-through payment" arrangement involving Pathos AI. These issues have raised doubts about the sustainability of Tempus’s core operations and revenue projections. Legal actions from multiple firms, including Glancy Prongay & Murray LLP and Pomerantz LLP, cite material misrepresentations in the company’s public statements. Investors are urged to act by August 12, 2025, to pursue claims under securities fraud allegations.

Market participants remain cautious as the lawsuits underscore broader concerns about financial transparency. The stock’s recent volatility aligns with ongoing skepticism from short-sellers and analysts, who have questioned the validity of key strategic partnerships. While no direct regulatory actions have been announced, the cumulative legal and operational risks continue to weigh on investor sentiment.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present, outperforming the benchmark return of 29.18% by 137.53%. This underscores the role of liquidity concentration in short-term stock performance, particularly in volatile markets.